Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P, Bhardwaj N. Kyi C, et al. Among authors: mandeli j. Clin Cancer Res. 2018 Oct 15;24(20):4937-4948. doi: 10.1158/1078-0432.CCR-17-1866. Epub 2018 Jun 27. Clin Cancer Res. 2018. PMID: 29950349 Free PMC article.
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Pavlick A, et al. Among authors: mandeli j. Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7. Cancer Immunol Res. 2020. PMID: 31699709 Free PMC article. Clinical Trial.
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Sabado RL, et al. Among authors: mandeli j. Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29. Cancer Immunol Res. 2015. PMID: 25633712 Free PMC article. Clinical Trial.
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Siegel AB, et al. Among authors: mandeli j. J Clin Oncol. 2008 Jun 20;26(18):2992-8. doi: 10.1200/JCO.2007.15.9947. J Clin Oncol. 2008. PMID: 18565886 Free PMC article. Clinical Trial.
Survival after combined modality therapy for pancreatic cancer.
Bruckner HW, Kalnicki S, Dalton J, Snady H, Schwartz GK, Chesser MR, Lehrer D, Mandeli J, Harpaz N, Janus C. Bruckner HW, et al. Among authors: mandeli j. J Clin Gastroenterol. 1993 Apr;16(3):199-203. doi: 10.1097/00004836-199304000-00006. J Clin Gastroenterol. 1993. PMID: 8505490 Clinical Trial.
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M, Sung M, Ferris R, Kao J, Wang LH, Pan PY, Ko EC, Chen SH. Chen HM, et al. Among authors: mandeli j. Clin Cancer Res. 2015 Sep 15;21(18):4073-4085. doi: 10.1158/1078-0432.CCR-14-2742. Epub 2015 Apr 28. Clin Cancer Res. 2015. PMID: 25922428 Free PMC article. Clinical Trial.
119 results